Premium
The derivation of clinical‐grade human embryonic stem cell lines
Author(s) -
Skottman Heli,
Dilber M. Sirac,
Hovatta Outi
Publication year - 2006
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2006.03.083
Subject(s) - embryonic stem cell , induced pluripotent stem cell , human induced pluripotent stem cells , regenerative medicine , microbiology and biotechnology , biology , cell therapy , cell culture , stem cell , kosr , inner cell mass , cell , embryo , genetics , embryogenesis , blastocyst , gene
The pluripotent nature of human embryonic stem cells (hESC) has attracted great interest in using them as a source of cells or tissue in cell therapy. However, in order to be used in regenerative medicine, the pluripotent hESC lines should be established and propagated according to good manufacturing practice quality requirements. The cultures should be animal substance free in order to exclude the risk of infections and immunogenity. They should also be genetically and epigenetically normal. The detailed molecular mechanisms of their pluripotency are still not defined. Using human feeder cells, a medium containing only human proteins, the mechanical isolation of the inner cell mass and mechanical passaging of hESC, is a safe option until a functional defined medium containing physiological concentrations of regulatory factors is available.